ACCLYR Trademark

Trademark Overview


On Monday, December 6, 2021, a trademark application was filed for ACCLYR with the United States Patent and Trademark Office. The USPTO has given the ACCLYR trademark a serial number of 97157217. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, November 16, 2023. This trademark is owned by Pfizer Inc.. The ACCLYR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; Syringes sold filled with anti-arrhythmics, anesthetics, electrolyte solutions, imaging agents or diluents
acclyr

General Information


Serial Number97157217
Word MarkACCLYR
Filing DateMonday, December 6, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, November 16, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 18, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; Syringes sold filled with anti-arrhythmics, anesthetics, electrolyte solutions, imaging agents or diluents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-219

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events


Event DateEvent Description
Saturday, November 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 16, 2023SOU EXTENSION 2 GRANTED
Thursday, November 16, 2023SOU EXTENSION 2 FILED
Thursday, November 16, 2023SOU TEAS EXTENSION RECEIVED
Saturday, May 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 11, 2023SOU EXTENSION 1 GRANTED
Thursday, May 11, 2023SOU EXTENSION 1 FILED
Thursday, May 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, December 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 18, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 18, 2022PUBLISHED FOR OPPOSITION
Wednesday, September 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 14, 2022ASSIGNED TO EXAMINER
Friday, December 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 9, 2021NEW APPLICATION ENTERED